A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.
Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)
1 - 3 av 3Sidstorlek: 50
Sortera efter: Utgivningsår
- 2017
-
Vasoactive peptides associate with treatment outcome ofbevacizumab-containing therapy in metastatic colorectal cancer
Helga Hagman, Pär-Ola Bendahl, Olle Melander, Jan Sundberg, Anders Johnsson & Mattias Belting, 2017, I : Acta Oncologica. 56, 5, s. 653-660Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
- 2016
-
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
Helga Hagman, Jan-Erik Frödin, Åke Berglund, Jan Sundberg, Lene Vestermark, Maria Albertsson, Eva Fernebro & Anders Johnsson, 2016 jan, I : Annals of Oncology. 27, 1, s. 140-147Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift
- 2013
-
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
Anders Johnsson, Helga Hagman, Jan-Erik Frödin, Åke Berglund, N. Keldsen, Eva Fernebro, J Sundberg, R De Pont Christensen, K-L Garm Spindler, D Bergström & A Jakobsen, 2013, I : Annals of Oncology. 24, 9, s. 2335-2341Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift